



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, Francesco D'Amore

Organisation/Company: Aarhus University Hospital

Country: Denmark

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
03/2019-03/2019	Kyowa Kirin	mogamalizumab	cutaneous T-cell lymphomas
04/2018-05/2018	Nordic Nanovector	Betalutin	Follicular lymphoma
05/2017-09/2017	Servier	Pixantrone	relapsed/refractory aggressive lymphomas
03/2019-03/2019	Takeda	Brentuximab Vedotin	T-cell lymphomas; Hodgkin lymphoma

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
03/2019-03/2019	Kyowa Kirin	mogamalizumab	Cutaneous T-cell lymphoma
04/2018-05/2018	Nordic Nanovector	Betalutin	Follicular lymphoma
05/2017-09/2017	Servier	Pixantrone	Relapsed/refractory aggressive lymphoma

2

03/2019-03/2019	Takeda	Brentuximab Vedotin	T-cell lymphomas; Hodgkin lymphoma
-----------------	--------	---------------------	------------------------------------

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
03/2018-(current)	Nordic Nanovector	Betalutin	Indolent lymphomas
01/2018-(current)	Incyte	Parsaclisib	mantle cell lymphoma

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

Lead author of the ESMO guidelines on peripheral T-cell lymphoma
 Chairman of the Working Group on T-cell lymphomas of the Nordic Lymphoma Group (www.nordic-lymphoma.org)
 Chairman of the Working Group on T-cell lymphomas of the Danish Lymphoma Group
 Member of the European Association of Haematology (EHA)
 Member of the American Society of Hematology (ASH)
 Chair of the Nordic Meeting on Tumor Microenvironment in Lymphoma
 Phase 2 trial: the PREBEN regimen (pixantrone, rituximab, etoposide, ofon bendamustine) in relapsed aggressive lymphoma

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Francesco D'Amore
Date:	2020-02-20

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template